AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03050827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active placebo for 3% oxybutynin
Trial: NCT03110133
Drug: Full Spectrum Microbiota
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered donor derived microbiota
Trial: NCT03110133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for CP101
Trial: NCT03890458
Drug: DEVIT-3
RxNorm normalized name: DEVILS CLAW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The physicians gave the women in the experimental group vitamin D oral drops in an ampoule of 300,000 IU and a vial of 50,000 IU to take during the IVF treatment. Written and verbal information about how to take vitamin D was provided to the participants by the nurses. The women took 300,000 IU vitamin D orally for the first week. In the second week of the treatment, 50,000 IU vitamin D (15 drops/day) was used as maintenance dose until the pregnancy test day.
Trial: NCT03995888
Drug: rhPSMA-7.3 (18F) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioligand for PET CT scanning
Trial: NCT01153256
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.6 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
Trial: NCT01153256
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.9 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
Trial: NCT01160991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules are given at 8:00 a.m.
Trial: NCT00329147
Drug: desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00245921
Drug: Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00543712
Drug: PRO95780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT01077427
Drug: Gemcitabine + Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine: 1000 mg/m² as iv-infusion on days 1, 8 and 15 of each course (Total dose: 18 g/m²)~Capecitabine: daily dose of 1660 mg/m²; administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles
Trial: NCT00770029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
Trial: NCT02509351
Drug: placeboo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: women will recive 2 identical tablets as placeboo
Trial: NCT01913964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (sugar pill)
Trial: NCT03529253
Drug: Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab group receive Alirocumab75mg/2week subcutaneous injection plus Rosuvastatin10mg/daily by oral for 9 months.
Trial: NCT03529253
Drug: Rosuvastatin calcium10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin10mg/daily by oral for 9 months.
Trial: NCT03666442
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xelox chemotherapy,that oxaliplatin 130mg/m2 d1,capecitabine 1000mg/m2 twice daily d1-14,every 3 weeks
Trial: NCT01076153
Drug: Clarithromycin (Klacid® MR)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Klacid MR 500mg (clarithromycin)
Trial: NCT00401921
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
Trial: NCT00401921
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
Trial: NCT03970655
Drug: Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 1
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the LEFT pterygopalatine fossa
Trial: NCT03970655
Drug: Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 2
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the RIGHT pterygopalatine fossa
Trial: NCT01085643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24mcg placebo capsule taken once
Trial: NCT02384187
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
Trial: NCT00715403
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03462173
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Capsule
Trial: NCT04028362
Drug: Neuromuscular Blocking Agents
RxNorm normalized name: NEUROMUSCULAR BLOCKING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient who will receive neuromuscular blockade will be follow during their ICU lenght stay.
Trial: NCT01316406
Drug: ATH008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo
Trial: NCT03854942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet daily
Trial: NCT00457730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are randomized to either Duloxetine or Placebo
Trial: NCT02150928
Drug: Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Enrolled patients will receive asparaginase Erwinia chrysanthemi 25,000 IU/m2 administered intramuscularly (IM) on a Monday/Wednesday/Friday schedule (all dosing regimens will start on a Monday)~* All patients will receive at least 1 course (2 weeks) of treatment with asparaginase Erwinia chrysanthemi (1 course=6 doses), and a maximum number of courses needed to complete their remaining asparaginase therapy (up to 15 courses)~* Eligible patients may not begin treatment with asparaginase Erwinia chrysanthemi until their serum asparaginase activity level is below the assay detectable limit
Trial: NCT00201643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Course of Placebo (NS)
Trial: NCT02187159
Drug: DS-5565
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-5565 15 mg tablet for oral administration
Trial: NCT02187159
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (matching DS5565) for oral administration
Trial: NCT02187159
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule (matching pregabalin) for oral administration
Trial: NCT02593721
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The active comparator group received an oral Ibuprofen treatment. The starting dose was of 400 mg/day and it was increased to a maximum of 1200 mg/day divided in 3 oral intakes every 8 hours depending on patient tolerance.The intervention was applied during a period of 6 weeks.
Trial: NCT01514253
Drug: Glucose 25%
RxNorm normalized name: glucose 25% oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml glucose 25%, once
Trial: NCT01406717
Drug: SPIL1033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
Trial: NCT01406717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
Trial: NCT01417143
Drug: TKI258 (Dovitinib):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
Trial: NCT03552705
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of oral placebo and intravenous saline during ACL reconstruction surgery
Trial: NCT03513016
Drug: UBX0101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug intra-articular injection
Trial: NCT02031523
Drug: Sanjie analgesic capsule
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.or follow the doctor's advice.
Trial: NCT02031523
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral，four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle. Or Follow the doctor's advice.
Trial: NCT03308669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01083342
Drug: MTX, MVD, VIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX: Methotrexate,Leucovorin MVD: Methotrexate,Vincristine,Dexamethasone VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)
Trial: NCT01366664
Drug: Treatment sequence 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days)
Trial: NCT00311363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, orally, once daily for 12 weeks following single blind 24-week phase
Trial: NCT01093846
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg every 4 weeks
Trial: NCT00492518
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00492518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01093846
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg every 2 weeks
Trial: NCT01093846
Drug: Placebo AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to AIN457
Trial: NCT03532711
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy treated patients
Trial: NCT00486005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02904759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02620813
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will apply 0.5% tretinoin cream nightly to their face for a total of 12 weeks.
Trial: NCT00978523
Drug: AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, dose-escalation
Trial: NCT00863915
Drug: Atlace® 10 mg capsules, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products sprinkled on one tablespoonful of applesauce
Trial: NCT01856738
Drug: Placebo (for rivastigmine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule. Dose 3,0 - 6,0 mg BID
Trial: NCT05108766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to tildrakizumab administered SC
Trial: NCT02261467
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) injected into the protocol-specified areas on Day 1.
Trial: NCT00699049
Drug: Alpha blocker
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00699049
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00234845
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00958503
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched tablets without active ingredient
Trial: NCT01353859
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-25 mg orally weekly
Trial: NCT04343287
Drug: BRM421
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active control with BRM421 solution
Trial: NCT04343287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The vehicle solution
Trial: NCT03909529
Drug: Spironolactone 25 mg/ 5 mL S/F Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
Trial: NCT02233218
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02587988
Drug: HGP0904
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02587988
Drug: Placebo (for HCP1302)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02587988
Drug: Placebo (for HGP0904)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01141556
Drug: Selenase
RxNorm normalized name: selenite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After enrollment, patients will be prospectively randomized into two groups: a placebo group without selenium and a group receiving a loading dose of selenium 4000 μg intraoperatively,followed by a daily dosage of 1000 μg until leaving the ICU (longest supplementation 13 days).
Trial: NCT02751541
Drug: Sunscreen Sport Spray (BAY987519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB#Y51-002)
Trial: NCT00700427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral delivery of matching placebo
Trial: NCT01917721
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The interventional arm of the study will receive doxycycline 4.4 mg/kg/day for 21 days besides receiveing standard care: IVIG and/or Remicade.
Trial: NCT01917721
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical care and placebo will be provided to the comparative arm of the study administering IVIG and/or Remicade, but not doxycycline.
Trial: NCT03040167
Drug: Bupivacaine with epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group
Trial: NCT03040167
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group
Trial: NCT02172144
Drug: Placebo matching BI 1744 CL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01669434
Drug: ACEI continuation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These chronic medications will be taken without interruption preoperatively.
Trial: NCT01669434
Drug: ACEI omission
RxNorm normalized name: Veneno de Abeja Aceite de Vibora
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Although taken chronically by patients in this intervention, the final preoperative dose of these medications will be omitted, whether it was scheduled for the morning of surgery or the day prior.
Trial: NCT00669370
Drug: docetaxel and capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: biweekly docetaxel iv (50 mg/m2) on day 1 and 15 and capecitabine po 1250 mg/m2 x 2/day days 1-7 and 15-21, treatment cycle consisting of 21 days
Trial: NCT00825123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose powder
Trial: NCT00044291
Drug: aromatase inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01851941
Drug: mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
Trial: NCT03577249
Drug: Dialysis Solutions
RxNorm normalized name: dialysis solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution A: 3mmol/L of acetate anion; Solution B: 1mmol/L of citrate anion
Trial: NCT01811732
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01944657
Drug: Standard Medication Monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These medications could include bupropion (Wellbutrin and others), citalopram (Celexa and others), Clomipramine (Ananfranil and others), duloxetine (Cymbalta), escitalopram (Lexapro and others), fluoxetine (Prozac and others), fluvoxamine (Luvox and others), imipramine (Tofranil and others), mirtazapine (Remeron and others), nortriptylatine (Pamelor, Aventyl, and others), paroxetine (Paxil, Pexeva, and others), phenelzine (Nardil), sertraline (Zoloft and others), tranylcypromine (Parnate and others), venlafaxine (Effexor and others).
Trial: NCT00814138
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study
Trial: NCT04126304
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: If the diagnosis is common cold, acute bronchitis or post-infection cough ，treated with non-macrolides when the mycoplasma colloidal gold test is negative, treated with azithromycin when colloidal gold test is positive.
Trial: NCT04126304
Drug: non-macrolides antibiotics
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the diagnosis is community-acquired pneumonia with negative mycoplasma antibody-granule agglutination, non-macrolides are used for treatment
Trial: NCT01253096
Drug: Intratumoral injections of L19IL2
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with intratumoral injections of L19IL2 1-3 x weekly. The maximum cumulative dose per week is 20 MioIU. Treatment duration is up to 20 weeks.
Trial: NCT02104661
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%.
Trial: NCT02104661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%.
Trial: NCT02603198
Drug: mepivacaine chloridrato epinephrine
RxNorm normalized name: epinephrine / mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: local anesthesia for tooth removal
Trial: NCT00774475
Drug: doubled therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clopidogrel 150 mg/day
Trial: NCT02976519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily
Trial: NCT00483652
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (sugar pill)
Trial: NCT01427335
Drug: calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes
Trial: NCT01427335
Drug: 0.9 % saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 % saline intravenous infusion
Trial: NCT01626066
Drug: LUM015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUM015 assigned dose given once by IV push
Trial: NCT00005645
Drug: ILX-295501
FDA approved: no
EMA approved: no
PMDA approved: no